Following a two-year investigation, Roche (RHHBY) was fined $14 million by antitrust authorities in Romania for using different tactics to impede competition to a pair of its cancer medicines, the latest effort by European governments to crack down on anti-competitive practices.

In one instance, Roche allegedly monopolized the market for Rituxan and Herceptin by undercutting rival bidders in auctions that were held to supply a national program for cancer medicines as well as hospitals. Specifically, the drug maker sold the medicines at higher wholesale prices to two distributors, which were also bidding, than to its own subsidiary, making it difficult for these companies to compete.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy